Valuation: PureTech Health plc

Market Cap 422M 370M 341M 319M 599M 39.81B 611M 4.1B 1.59B 19.68B 1.58B 1.55B 68.23B P/E 2026 *
-3.79x
P/E 2027 * -4.2x
Enterprise Value 184M 161M 148M 139M 261M 17.32B 266M 1.78B 690M 8.56B 690M 675M 29.69B EV / Sales 2026 *
25.9x
EV / Sales 2027 * 14.1x
Free-Float
84.5%
Yield 2026 *
-
Yield 2027 * -
1 day-1.37%
1 week+0.92%
Current month-5.48%
1 month-4.65%
3 months+14.09%
6 months+3.96%
Current year+4.96%
1 week 126.2
Extreme 126.2
135.6
1 month 121.6
Extreme 121.6016
143.6
Current year 107.4
Extreme 107.4
143.6
1 year 104.71
Extreme 104.712
148
3 years 100.4
Extreme 100.4
238.5
5 years 100.4
Extreme 100.4
410.66
10 years 100.4
Extreme 100.4
447.66
Manager TitleAgeSince
Chief Executive Officer 43 2025-07-14
President 53 2024-04-08
Chief Operating Officer - 2021-07-31
Director TitleAgeSince
Director/Board Member 76 2015-05-07
Director/Board Member 76 2008-12-31
Director/Board Member 73 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
03-12Buy

Founder

112,509 0.0466%
25-09-23Buy

Chairman

65,250 0.0272%
25-09-23Buy

Director

59,100 0.0246%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%+0.92%+5.47%-42.20% 423M
-0.48%+8.75%-5.51%+0.91% 46.36B
+2.19%+9.81%+385.81%+632.13% 37.88B
+2.53%+13.90%+20.85%-10.61% 31.12B
+1.65%+2.98%+9.98%+55.42% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-0.32%+14.36% - - 16.25B
+1.37%+15.67%+71.80%+134.14% 14.85B
+1.00%+9.67%+14.90%+21.88% 13.58B
+3.63%+6.97%+104.07%+107.62% 12.95B
Average +0.52%+7.19%+68.43%+101.70% 22.87B
Weighted average by Cap. +0.58%+7.65%+85.39%+138.44%

Financials

2026 *2027 *
Net sales 7.1M 6.23M 5.74M 5.37M 10.07M 670M 10.28M 68.97M 26.69M 331M 26.66M 26.08M 1.15B 13.47M 11.81M 10.88M 10.19M 19.11M 1.27B 19.5M 131M 50.62M 628M 50.57M 49.46M 2.18B
Net income -124M -109M -101M -94.18M -177M -11.74B -180M -1.21B -468M -5.8B -467M -457M -20.12B -97.27M -85.28M -78.61M -73.6M -138M -9.18B -141M -945M -366M -4.53B -365M -357M -15.72B
Net Debt -238M -209M -193M -180M -338M -22.49B -345M -2.32B -896M -11.11B -895M -876M -38.54B -232M -204M -188M -176M -330M -21.91B -336M -2.26B -873M -10.83B -872M -853M -37.55B
Logo PureTech Health plc
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Employees
90
Date Price Change Volume
26-06-26 GBX 131.20 -0.30% 188,259
26-06-25 GBX 131.60 -1.94% 474,718
26-06-24 GBX 134.20 +1.67% 267,618
26-06-23 GBX 132.00 -0.45% 261,827
26-06-22 GBX 132.60 +0.91% 400,103
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.734USD
Average target price
5.151USD
Spread / Average Target
+197.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTC Stock